Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Abeona Therapeutics Inc.

NASDAQ: ABEO · Life Sciences · 9 alerts · CIK 318306

Share price
$2.60Close, Nov 16
Market cap
$149M
Shares outstanding
57.15MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Abeona Therapeutics Inc. filings on SEC EDGAR ↗

4:32 PM ET 10-Q
Financial Results

Abeona Therapeutics Q3 2026 Results: Net Loss of $4.81M, Loss Narrows

Abeona Therapeutics reported a decrease in cash and short-term investments to $134.9 million as of September 30, 2026, compared to $191.4 million at year-end 2025. The company is focused on the commercialization of ZEVASKYN and the development of ABO-801, while noting a private placement transaction announced on November 9, 2026.

Key figure
Net loss $4.81M
6:36 AM ET 8-K
Financial Results

Abeona Therapeutics Financial Results

Abeona Therapeutics reported Q3 2026 financial results, highlighted by $13.5 million in net ZEVASKYN revenue, an 18% sequential increase. The company completed six ZEVASKYN treatments during the quarter and expanded its qualified treatment center network to eight sites. Additionally, Abeona announced the acquisition of a Phase 3-ready asset, APT-1011, for eosinophilic esophagitis and a $30 million PIPE financing.

Term
Q3 2026

“Maximizing the opportunity for ZEVASKYN remains our number one priority. During the third quarter, we continued to build the commercial foundation for ZEVASKYN, with expansion of our QTC network and more centers gaining firsthand treatment experience.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics

“The acquisition of APT-1011 represents an important step in building Abeona into a diversified commercial-stage company, adding a uniquely differentiated late-stage orphan-drug asset with substantial commercial potential in a rapidly growing disease with high unmet need.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.